Owlstone Medical said today that it inked a strategic collaborative deal with Johnson & Johnson‘s (NYSE:JNJ) Actelion to discover and validate a breath-based test intended for the early diagnosis of pulmonary hypertension and its subtypes. Cambridge, UK-based Owlstone Medical said that the collaborative development program will be funded solely by Actelion, and that it will initially […]
Here are the pharma companies accused of blocking generic competition
To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]
Johnson & Johnson closes $30B Actelion buyout
Johnson & Johnson (NYSE:JNJ) closed its $30 billion buy of Swiss biotech firm Actelion, the company reported today. The US healthcare giant bought Actelion in an all-cash deal for $280 per share. The acquisition is expected to add $1.3 billion in sales for Johnson & Johnson in 2017, according to the company. Get the full […]
Johnson & Johnson wins last regulatory nod needed for Actelion acquisition
Johnson & Johnson (NYSE:JNJ) said today that the European Commission approved its acquisition of Swiss biotech Actelion. The regulatory nod was the last approval needed to complete the company’s transaction. The U.S. healthcare giant added that it expects the settlement of the $30 billion all-cash tender offer on June 16. Get the full story at […]
After review of patient deaths, European regulators OK Actelion’s Uptravi
The European Medicines Agency told doctors today that they can continue to prescribe Actelion‘s (VTX:ATLN) pulmonary arterial hypertension drug, Uptravi. The regulatory body initiated a safety review in January after 5 patients in France died and docs were asked to stop prescribing the drug. Regulators reported that their review did not suggest an increase in mortality […]
Actelion shareholders OK R&D spinout
Actelion (VTX:ATLN) shareholders today reportedly approved spinning off the company’s early clinical assets and drug discovery branch into a new company. The move keeps Johnson & Johnson (NYSE:JNJ) $30 billion takeover on track to close in the 2nd quarter. The newly formed biopharmaceutical company will be called Idorsia Ltd and led by Actelion CEO Jean-Paul Clozel. Shares in Idorsia […]
Johnson & Johnson’s tender offer for Actelion snares 78% stake
Johnson & Johnson (NYSE:JNJ) said today that it controls nearly 78% of voting rights in its $30 billion acquisition of Swiss biotech firm Actelion (VTX:ATLN). Janssen, J&J’s Swiss subsidiary, declared the tender offer successful. The company added that based on regulatory approval proceedings, the offer is expected to settle in the 2nd quarter of this year. Get the full […]
How Sanofi blew its chance with Actelion
Days before entering into exclusive takeover negotiations with Johnson & Johnson (NYSE:JNJ), Actelion (VTX:ATLN) was reportedly fielding an offer from Sanofi (NYSE:SNY). But the Swiss biotech eventually agreed to go with J&J’s $30 billion bid in an all-cash deal at the end of January. Actelion accepted the U.S. healthcare giant’s offer because it provided more certainty, Reuters reported today. The prospectus […]
Actelion reports income, revenue growth in FY2016
(Reuters) – Swiss drugmaker Actelion‘s 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension (PAH), it said on Tuesday. Core net income rose to 881 million Swiss francs ($877.8 million) from 693 million francs in the previous year, the company said in a statement. […]
Johnson & Johnson to pay $30B for Actelion
After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]
J&J, Actelion still in talks despite Opsumit failure
Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart […]
MassDevice Network
@MassDevice
LinkedIn
YouTube